Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Background The implementation of genotyping for anti-hypertensive drugs in clinical
practice remains a challenge. We conducted this study to analyze the distribution of …

Recent reports indicate a potential oncogenic role of antihypertensive drugs in common
cancers. However, it remains uncertain whether this phenomenon influences the risk of …

Recent CYP2D6 phenotype standardization efforts by CYP2D6 activity score (AS) are based
on limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Using data from two …

Aim: To investigate the association between beta1-adrenergic receptor (ADRB1)
polymorphisms and response to bisoprolol treatment in beta-blocker naive patients with …

Single nucleotide polymorphisms (SNPs) have been associated with differential beta-
blocker (BB) effects on heart rate, blood pressure, and left ventricular ejection fraction in …

In the area of drug development and clinical pharmacotherapy, a profound understanding of
the pharmacokinetics and potential adverse reactions associated with the drug under …

Previously in this Journal, we reported that severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) spike (S) blocked sorting nexin 27 (SNX27)-mediated endocytic recycling of …

Pharmacogenomics is the examination of how genetic variation influences drug metabolism
and response, in terms of both efficacy and safety. In cardiovascular disease, patient …